Some examples are adverse effects to epidermal growth factor (EGFR) inhibitors (e.g., papulopustular exanthemas in up to 80% of patients, also xerosis, hypotrichosis, whitlow) or the hand-foot syndrome associated with the use of vascular endothelial growth factor (VEGF) inhibitors (sorafenib, sunitinib) [16, 43]. This evidence concerns the gene VEGFA and Dry skin.